ClinicalTrials.gov
ClinicalTrials.gov Menu

Fatty Liver and Obstructive Sleep Apnea

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00730873
Recruitment Status : Completed
First Posted : August 8, 2008
Last Update Posted : August 8, 2008
Sponsor:
Information provided by:
Assaf-Harofeh Medical Center

Brief Summary:
Non-alcoholic fatty liver disease is associated with obstructive sleep apnea. Abnormalities in liver enzymes can improve following continuous positive airway pressure in patients with obstructive sleep apnea. Computerized tomography can be used to quantify fatty liver changes. We hypothesize that continuous positive airway pressure can reduce morphologic fatty liver changes in patients with obstructive sleep apnea and non-alcoholic fatty liver, an that this reduction can be evident using computerized tomography

Condition or disease Intervention/treatment Phase
Non-Alcoholic Fatty Liver Disease Obstructive Sleep Apnea Device: Continuous positive airway pressure Not Applicable

Study Type : Interventional  (Clinical Trial)
Primary Purpose: Treatment
Official Title: Fatty Liver and Obstructive Sleep Apnea


Arm Intervention/treatment
Experimental: A
continuous positive airway pressure
Device: Continuous positive airway pressure



Primary Outcome Measures :
  1. Reduction in fatty liver changes on computerized tomography [ Time Frame: Within 1-2 years ]

Secondary Outcome Measures :
  1. Improved liver enzymes abnormalities [ Time Frame: Within 1-2 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   30 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Obstructive sleep apnea, defined as AHI>5/h

Exclusion Criteria:

  • Consumption of more than 20 grams of alcohol per 24 h
  • Known autoimmune disease
  • Usage of known hepatotoxic drugs
  • Medical history positive for viral hepatitis or other chronic liver disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00730873


Locations
Israel
The pulmonary institute, Asaf Harofeh Medical Center
Zerifin, Israel, 70300
Sponsors and Collaborators
Assaf-Harofeh Medical Center

ClinicalTrials.gov Identifier: NCT00730873     History of Changes
Other Study ID Numbers: 135/07
First Posted: August 8, 2008    Key Record Dates
Last Update Posted: August 8, 2008
Last Verified: August 2008

Additional relevant MeSH terms:
Apnea
Sleep Apnea Syndromes
Sleep Apnea, Obstructive
Liver Diseases
Fatty Liver
Non-alcoholic Fatty Liver Disease
Respiration Disorders
Respiratory Tract Diseases
Signs and Symptoms, Respiratory
Signs and Symptoms
Sleep Disorders, Intrinsic
Dyssomnias
Sleep Wake Disorders
Nervous System Diseases
Digestive System Diseases